Westaim announced IPO for NUCRYST subsidiary

Guest Contributor
December 9, 2005

Westaim Corp has announced an initial public offering (IPO) for its subsidiary NUCRYST Pharmaceuticals Corp, which develops medical products based on its nanocrystalline silver technology. The IPO is open to Canadian and US investors, with shares offered by an underwriting team led by Jeffries and Co Ltd. Westaim will retain a controlling interest in NUCRYST.

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.